Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis
NCT02743871 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 97
Last updated 2022-05-19
Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06817024 in healthy volunteers, in participants with chronic rhinosinusitis, with nasal polyps and in participants with moderate-to-severe Atopic Dermatitis
Conditions
Interventions
- BIOLOGICAL
-
PF-06817024
Subjects will be given one dose of PF-06817024 intravenously
- OTHER
-
Placebo for PF-06817024
Subjects will be given one dose of placebo for PF-06817024 intravenously
- BIOLOGICAL
-
PF-06817024
Subjects will be given one dose of PF-06817024 subcutaneously
- OTHER
-
Placebo for PF-06817024
Subjects will be given one dose of placebo for PF-06817024 subcutaneously
- BIOLOGICAL
-
PF-06817024
Subjects will be given two doses of PF-06817024 intravenously
- OTHER
-
Placebo for PF-06817024
Subjects will be given two doses of PF-06817024 intravenously
- BIOLOGICAL
-
PF-06817024
Subjects will be given 2 doses intravenously
- OTHER
-
Placebo for PF-06817024
Subjects will be given 2 doses intravenously
- BIOLOGICAL
-
PF-06817024
Subjects will be given doses of PF-06817024 intravenously
- OTHER
-
Placebo for PF-06817024
Subjects will be given doses of Placebo intravenously
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-04-27
- Primary Completion
- 2021-03-09
- Completion
- 2021-03-09
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
NCT06454240 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
NCT07313917 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
NCT06850805 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps
NCT02170337 ·Status: COMPLETED ·Phase: PHASE1
-
Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease
NCT01013701 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps
NCT07132827 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps
NCT05873803 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT06015243 ·Status: UNKNOWN ·Phase: PHASE2
-
Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis
NCT03472144 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma
NCT03681093 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT05891483 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps
NCT06516302 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
GB001 in Adult Participants With Chronic Rhinosinusitis
NCT03956862 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps
NCT06036927 ·Status: COMPLETED ·Phase: PHASE2
-
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
NCT06691113 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video
NCT03591068 ·Status: COMPLETED ·Phase: PHASE3
-
A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps
NCT02912468 ·Status: COMPLETED ·Phase: PHASE3
-
An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
NCT01920893 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP
NCT06398873 ·Status: RECRUITING
-
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps
NCT03960580 ·Status: COMPLETED ·Phase: PHASE3
-
Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
NCT02898454 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)
NCT04607005 ·Status: COMPLETED ·Phase: PHASE3
-
Anti-Inflammatory Agent in Sinusitis
NCT02874144 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab
NCT03369574 ·Status: WITHDRAWN